Loading…
Celcuity Inc. is projected to rise to $95.57 by 2027, a +9% move from its current price of $87.64. CELC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $84.13 | $87.67 | $91.37 | +0.04% |
| Aug 2 | $82.74 | $87.71 | $92.98 | +0.08% |
| Aug 3 | $81.69 | $87.74 | $94.25 | +0.12% |
| Aug 4 | $80.83 | $87.78 | $95.33 | +0.16% |
| Aug 5 | $80.07 | $87.81 | $96.30 | +0.20% |
| Aug 6 | $79.40 | $87.85 | $97.19 | +0.24% |
| Aug 7 | $78.79 | $87.88 | $98.02 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $78.79 | $87.88 | $98.02 | +0.28% |
| Week 2 | $75.52 | $88.13 | $102.85 | +0.56% |
| Week 3 | $73.15 | $88.38 | $106.77 | +0.84% |
| Week 4 | $71.24 | $88.62 | $110.25 | +1.12% |
| Week 5 | $69.62 | $88.87 | $113.45 | +1.40% |
| Week 6 | $68.20 | $89.12 | $116.44 | +1.69% |
| Week 7 | $66.94 | $89.37 | $119.30 | +1.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors in the United States.
Its lead drug Gedatolisib selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2, to treat patients with HR+ and/or HER2- or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer.
Celcuity was incorporated in 2011 and is based in Minneapolis, Minnesota. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. (CELC) is a healthcare company with a current price of $82.62 and a market capitalization of $4.03B. It is ranked 1424.
The latest sentiment is NEUTRAL, with a relative strength index (RSI) of 40 and moving-average references showing the 50-day SMA at $106.14 and the 200-day SMA at $102.65.
The near-term picture includes a 30-day price range from $61.67 to $110.68, with a support level at $87.32 and a resistance at $115.72. Annualized volatility stands at 80%.
A major floor 29.5% below — a decisive break under it would weaken the trend.
The nearest floor, 6.1% below — buyers have tended to step in here.
The nearest ceiling, 32.0% above — a clean break opens room to run.
A major ceiling 65.4% above — clearing it would confirm fresh momentum.
Key CELC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CELC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $83.65 | Buy | $85.41 | Buy |
| MA 10 | $86.48 | Buy | $87.66 | Sell |
| MA 20 | $96.08 | Sell | $91.96 | Sell |
| MA 50 | $101.43 | Sell | $99.84 | Sell |
| MA 100 | $110.74 | Sell | $103.54 | Sell |
| MA 200 | $103.53 | Sell | $95.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.48 | Neutral |
| Stoch RSI (14) | 35.62 | Neutral |
| CCI (20) | -51.92 | Neutral |
| Williams %R (14) | -81.34 | Info |
| MACD (12,26,9) | -0.88 | Sell |
| ROC (12) | -21.08 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 18.66 | Buy |
| TRIX (15) | -0.58 | Sell |
| Awesome (5,34) | -11.50 | Sell |
| Ultimate (7,14,28) | 36.77 | Neutral |
| Momentum (10) | -0.65 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 82.41 | Buy |
| ADX (14) | 20.60 | Sell |
| ATR (14) | 3.38 | Info |
The 30-day picture is NEUTRAL, with RSI(14) at 40.
The stock’s 50-day moving average is $106.14 and the 200-day moving average is $102.65, providing a framework for near-term momentum.
The 30-day trading range spans $61.67 to $110.68, with near-term support at $87.32 and resistance at $115.72. Annualized volatility is 80%, indicating substantial price movement potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $82.27 | $87.64 | $122.60 | 0% | Neutral | |
| $72.66 | $95.57 | $134.81 | +9% | Neutral | |
| $82.69 | $113.77 | $169.22 | +30% | Bullish | |
| $80.55 | $115.11 | $178.31 | +31% | Bullish | |
| $87.73 | $129.68 | $207.78 | +48% | Bullish | |
| $119.37 | $182.03 | $300.29 | +108% | Bullish | |
| $129.24 | $202.96 | $343.61 | +132% | Bullish | |
| $130.59 | $210.87 | $365.44 | +141% | Bullish | |
| $126.34 | $209.53 | $370.95 | +139% | Bullish | |
| $125.52 | $213.62 | $385.71 | +144% | Bullish | |
| $186.71 | $358.68 | $702.58 | +309% | Bullish | |
| $380.33 | $845.18 | $1,858.89 | +864% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $82.27 | $87.64 | $102.63 | +0.00% |
| August 2026 | $77.62 | $92.09 | $112.54 | +5.08% |
| September 2026 | $75.63 | $90.88 | $113.28 | -1.32% |
| October 2026 | $73.51 | $89.25 | $112.98 | -1.80% |
| November 2026 | $75.62 | $92.60 | $118.70 | +3.76% |
| December 2026 | $76.63 | $94.57 | $122.60 | +2.13% |
Click any year to see its month-by-month CELC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CELC to range from $82.27 to $122.60 through 2026. The $87.64 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CELC price prediction for 2027 points to an average of $95.57 (low $72.66, high $134.81) — a potential gain of +9% on today's $87.64. A consolidation phase looks the most probable path here.
In 2028, CELC is projected to trade between $82.69 and $169.22, averaging $113.77 — a potential gain of +30% from today's $87.64. That is up +19% on the projected 2027 average. Momentum favours further upside here.
Celcuity Inc.'s 2029 outlook centres on $115.11, within a $80.55 to $178.31 range. That is up +1% on the projected 2028 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CELC could reach as high as $207.78, with a base case around $129.68 and support toward $87.73 — roughly +48% from $87.64. Momentum favours further upside here.
Expect CELC to range from $119.37 to $300.29 through 2031. The $182.03 average target implies a +108% move from current prices. That is up +40% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CELC price prediction for 2032 points to an average of $202.96 (low $129.24, high $343.61) — a potential gain of +132% on today's $87.64. Momentum favours further upside here.
In 2033, CELC is projected to trade between $130.59 and $365.44, averaging $210.87 — a potential gain of +141% from today's $87.64. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Celcuity Inc.'s 2034 outlook centres on $209.53, within a $126.34 to $370.95 range. That is -1% versus the projected 2033 average. That marks a +139% change versus current levels. Momentum favours further upside here.
By 2035, CELC could reach as high as $385.71, with a base case around $213.62 and support toward $125.52 — roughly +144% from $87.64. Buyers look set to stay in control over this stretch.
Expect CELC to range from $186.71 to $702.58 through 2040. The $358.68 average target implies a +309% move from current prices. That is up +68% on the projected 2035 average. Momentum favours further upside here.
The CELC price prediction for 2050 points to an average of $845.18 (low $380.33, high $1,858.89) — a potential gain of +864% on today's $87.64. Buyers look set to stay in control over this stretch.
Investing $1,000 in CELC today (≈ 11.410315 CELC) could be worth
$9,643.76
+$8,643.76 (+864%) by 2050 · US Dollar
Based on the average projected CELC price of $845.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CELCwould be worth at today's price.
$1,000 invested in CELC on Jul 30, 2025 (≈ 24.813896 CELC) would be worth
$2,174.69
+$1,174.69 (+117.5%) today · 2.17× · US Dollar
Based on a CELC entry price of $40.3 vs. today's $87.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $88.34 | $992.08 | -0.8% |
| 1 month ago | $104.62 | $837.7 | -16.2% |
| 3 months ago | $125.65 | $697.49 | -30.3% |
| 6 months ago | $109.42 | $800.95 | -19.9% |
| 1 year ago | $40.3 | $2,174.69 | +117.5% |
| All time (5.0y) ago | $20.21 | $4,336.47 | +333.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CELC forecast.
Our base-case forecast reaches $180.00 around 2031.
Implied market cap at $180.00: $8.78B
The multi-year forecast shows a bullish trajectory after 2026, with notable upside by 2030 and beyond. In 2026 the min and avg are both $82.62 and the max is $116.21, with an ROI of 0% and NEUTRAL sentiment. By 2027 the avg is $88.51 (min $66.51, max $126.65) and ROI 7.1% with NEUTRAL sentiment, followed by stronger implied gains in 2028 (avg $106.21, max $160.69; ROI 28.6%, BULLISH).
In 2029 the avg is $103.77 (min $71.25, max $163.87) with ROI 25.6% and BULLISH sentiment, and in 2030 the avg is $116.30 (min $76.95, max $190.28) with ROI 40.8% and BULLISH sentiment. The forecast continues rising through 2031–2035 (averages of $168.64, $184.27, $189.67, $189.68, and $188.10 respectively; all with BULLISH sentiment and growing ROIs of 104.1%, 123%, 129.6%, 129.6%, and 127.7%). By 2040 the average is $320.39 and the max $646.84, with ROI 287.8% and BULLISH sentiment, and by 2050 the average reaches $742.85 with a max of $1,691.79, a strong 799.1% ROI and BULLISH sentiment.
These figures reflect longer-term upside potential, though they remain estimates and not guarantees. Gedatolisib and the Pfizer licensing context provide the fundamental backdrop for this trajectory, but actual results will depend on clinical, regulatory, and market developments.
Tap a question to reveal the answer.
The average forecast price in 2030 is $116.30 per share with an estimated ROI of 40.8%.
The forecast shows a bullish trajectory from 2028 onward, with the average price rising toward $742.85 by 2050 and a maximum potential ROI of 799.1%. Near term (2026–2027) is neutral, so investors should consider the mix of near-term caution and long-term upside.
Yes. The forecast includes years with max values above $200: 2031 max $284.50, 2032 max $319.45, 2033 max $336.95, 2034 max $344.56, 2035 max $348.82, and 2040 max $646.84, with even higher upside by 2050 (max $1,691.79).
Current price is $82.62 and market capitalization is $4.03B.
The 2050 average is $742.85 with a maximum of $1,691.79 and a bullish sentiment; the ROI is expected to be 799.1%.
Celcuity Inc. Community Discussion
0Share your Celcuity Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.